top of page

BridgeBio Pharma, Inc. (BBIO)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Investors who purchased BridgeBio shares are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether BridgeBio and certain of its officers and/or directors have violated federal securities laws.


On December 27, 2021, BridgeBio issued a press release “announc[ing] topline results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase 3 study investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).”  BridgeBio’s press release disclosed that the study failed to meet its primary endpoint.  On this news, BridgeBio’s stock price fell $29.24 per share, or 71.98%, to close at $11.38 per share on December 27, 2021.

If you are aware of any facts relating to this investigation or purchased BridgeBio shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

bottom of page